Video
Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-Naïve CLL/SLL
Author(s):
Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Ibrutinib is a first-in-class, oral, Bruton's tyrosine kinase inhibitor that is FDA approved for patients with CLL who received more than one prior therapy, as well as for patients with del17p.
The phase III randomized study evaluated ibrutinib in treatment-naïve patients 60 to 65 years old who did not have the 17p deletion. Both regimens were found to be well tolerated. However, patients who received ibrutinib had higher progression-free survival, overall survival, overall response rate, event-free survival, and hematologic improvement versus those who received chlorambucil. There was also an 84% reduction in the risk of death in the ibrutinib arm.
<<<
